Aclarion Stock Price, News & Analysis (NASDAQ:ACON) $0.26 -0.01 (-2.96%) (As of 12:29 PM ET) Add Compare Share Share Today's Range$0.26▼$0.3050-Day Range$0.26▼$0.5752-Week Range$0.25▼$2.37Volume29,698 shsAverage Volume765,644 shsMarket Capitalization$2.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About Aclarion Stock (NASDAQ:ACON)Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.Read More ACON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACON Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comShort Interest in Aclarion, Inc. (NASDAQ:ACON) Expands By 59.7%November 29, 2023 | americanbankingnews.comAclarion (NASDAQ:ACON) and BioNexus Gene Lab (NASDAQ:BGLC) Financial SurveyNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 27, 2023 | finance.yahoo.comAclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan ExamsNovember 9, 2023 | finance.yahoo.comAclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan AdoptionNovember 6, 2023 | markets.businessinsider.comAclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MDOctober 25, 2023 | finance.yahoo.comAclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to DenverOctober 24, 2023 | finance.yahoo.comAclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM MeetingNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 2, 2023 | finance.yahoo.comAclarion Provides Updated Investor Presentation and Corporate UpdateSeptember 8, 2023 | barrons.comAclarion Inc.August 25, 2023 | finance.yahoo.comAclarion, Inc. Announces Filing of Delayed 10-Q Quarterly ReportJune 14, 2023 | finance.yahoo.comAclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MIJune 8, 2023 | benzinga.comWhy Aclarion Stock Is Popping TodayJune 8, 2023 | msn.comACON Skyrockets after Presentation of Nociscan AbstractJune 8, 2023 | finance.yahoo.comAclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual MeetingMay 30, 2023 | finance.yahoo.comAclarion Announces New Engagement with The London Clinic and London Spine ClinicMay 23, 2023 | finance.yahoo.comAclarion, Inc. Announces Delayed 10-Q FilingMay 23, 2023 | finance.yahoo.comAclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MDMay 19, 2023 | msn.comAclarion gets $2M debt financingMay 19, 2023 | finance.yahoo.comAclarion Announces Non-Convertible Debt Financing to Achieve Three Critical CatalystsMay 10, 2023 | proactiveinvestors.comAclarion providing less invasive solution to treat lo back pain through augmented intelligenceApril 28, 2023 | finance.yahoo.comAclarion to Host Thought Leadership Symposium at SPINEWEEK 2023April 24, 2023 | ca.finance.yahoo.comAclarion, Inc. (ACON) Interactive Stock Chart - Yahoo FinanceApril 24, 2023 | finance.yahoo.comAclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical TrialApril 24, 2023 | benzinga.comWhy Aclarion Shares Are Soaring TodayApril 24, 2023 | msn.comAclarion Surges on Promising Nociscan Data in DLBPSee More Headlines Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACON CUSIPN/A CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,070,000.00 Net Margins-5,433.03% Pretax Margin-5,431.85% Return on Equity-724.93% Return on Assets-220.64% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$60,000.00 Price / Sales38.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book0.94Miscellaneous Outstanding Shares8,790,000Free Float6,832,000Market Cap$2.32 million OptionableNot Optionable Beta1.48 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jeffrey John Thramann M.D. (Age 58)Executive Chairman Comp: $318.75kMr. Brent Ness (Age 56)CEO, President & Director Comp: $418.75kMr. John Lorbiecki (Age 59)Chief Financial Officer Comp: $314.87kKey CompetitorsOpGenNASDAQ:OPGNNuwellisNASDAQ:NUWEAllarity TherapeuticsNASDAQ:ALLRIntelligent Bio SolutionsNASDAQ:INBSZyVersa TherapeuticsNASDAQ:ZVSAView All CompetitorsInsidersJeffrey John ThramannBought 1 shares on 2/16/2023Total: $1,000.00 ($1,000.00/share)John Paul LorbieckiBought 22,404 shares on 12/29/2022Total: $10,081.80 ($0.45/share)Brent NessBought 2,289 shares on 12/28/2022Total: $961.38 ($0.42/share)View All Insider Transactions ACON Stock Analysis - Frequently Asked Questions How have ACON shares performed in 2023? Aclarion's stock was trading at $0.58 at the beginning of the year. Since then, ACON shares have decreased by 54.8% and is now trading at $0.2621. View the best growth stocks for 2023 here. Are investors shorting Aclarion? Aclarion saw a increase in short interest in November. As of November 15th, there was short interest totaling 35,300 shares, an increase of 59.7% from the October 31st total of 22,100 shares. Based on an average daily volume of 172,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.7% of the company's shares are sold short. View Aclarion's Short Interest. When is Aclarion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ACON earnings forecast. When did Aclarion IPO? (ACON) raised $12 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share. How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACON) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.